ClinicalTrials.gg
RecruitingNCT07377643Updated Feb 25, 2026

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

A Phase 3 interventional study of Trastuzumab and IBI354 in HER2-positive Breast Cancer, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,932 studies in Breast Neoplasms with a site in China — 870 open to participants now, 1,067 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
205th of 1,522
540 · median 120
Started
2026
with 187 others
Phase 3
331 of 1,932
120 open now
Primary completion
2028-04
later than 832 of 1,066 live
Registered
1,729th of 1,932
by date

Among the 1,932 studies in Breast Neoplasms with a site in China, this one is the 205th largest by planned enrollment of the 1,522 interventional ones that give a count, is one of 188 that started in 2026, is one of 331 in phase 3, reaches primary completion later than 832 of the 1,066 other live ones, and was the 1,729th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

870 of the 1,932 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

865 more — sign in →

All 870 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,932 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a randomized, multicenter, open-label, phase 3 study evaluating the efficacy, safety, and tolerability of IBI354 combined with or without pertuzumab vs. THP as first-line treatment for HER2-positive unresectable, locally advanced or metastatic breast cancer.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants are eligible to be included in the study only if they meet all of the following criteria:

  1. Have signed the form (ICF) and are able to comply with the follow-up visits and related procedures required in the protocol.
  2. Male or female participants: ≥18 years of age
  3. confirmed breast cancer:

    1. Unresectable, locally advanced or breast cancer, i.e. participants who cannot be treated with curative intent and confirmed -positive (HER2 IHC 3+ or HER2 ISH+) on specimens taken after confirmed locally advanced or metastatic disease by central testing.
    2. Documented history of hormone receptor (HR)-positive (defined as estrogen receptor [ER] and/or progesterone receptor [PgR] positive [ER or PgR ≥1%]) or HR-negative after local testing in the metastatic setting according to ASCO/CAP guidelines. If a participant has more than one ER/PgR result after metastatic disease, the most recent result will be used.
  4. No prior chemotherapy or HER2-targeted therapy for unresectable, locally advanced or metastatic breast cancer ( endocrine therapy is allowed for patients with metastatic breast cancer). Participants who have received chemotherapy or HER2-directed therapy in the or adjuvant therapies and have a DFI of >6 months from completion of systemic chemotherapy or HER2-targeted therapy to advanced or metastatic diagnosis are eligible.
  5. Performance Status (ECOG PS) score of 0 or 1.
  6. Evidence of radiographic or objective disease progression on or after the last systemic therapy prior to starting study treatment.
  7. Have a of ≥12 weeks at screening.
  8. At least 1 as defined per v1.1 that has not been previously irradiated. Must be ≥ 10 mm in long axis (except for lymph nodes, which must be ≥ 15 mm in short axis) when accurately measured at baseline by CT or MRI (preferably with intravenous contrast) and the lesion is suitable for repeated accurate measurement.
  9. (LVEF) ≥ 50% within 28 days prior to randomization.
  10. Adequate organ and bone marrow function. Laboratory test values within 7 days prior to the first dose of the product meet the following requirements in (if the laboratory tests during the screening period do not meet the following requirements, only one retest is allowed during the screening period):

    1. (HGB) ≥ 90 g/L (transfusion of red blood cells or erythropoietin are not allowed within 1 week prior to the screening assessment, and participants requiring ongoing transfusion or growth factor support to maintain hemoglobin ≥ 90 g/L are not eligible).
    2. (ANC) ≥ 1.5 × 109 /L or within the normal range (G-CSF is not allowed within 1 week prior to the screening assessment).
    3. (PLT) ≥ 90 × 109 /L (transfusion with platelets or thrombopoietin is not allowed within 1 week prior to screening assessment, participants requiring thrombopoietic growth factors to maintain adequate platelet count are not eligible).
    4. Total (TBIL) ≤ 1.5 × (ULN) in the absence of liver metastasis; TBIL \< 3 × ULN in the presence of Gilbert syndrome (unconjugated hyperbilirubinemia) or liver metastasis.
    5. (ALT) and aspartate aminotransferase (AST) ≤3×ULN (\<5×ULN for participants with liver metastases).
    6. Serum albumin ≥ 25 g/L.
    7. Serum creatinine ≤ 1.5 × ULN, or ≥ 60 mL/min ( calculated using the Cockcroft-Gault formula ); if urinalysis indicates that the urine protein is \< 2+, participants with urine protein ≥ 2+ from urinalysis at baseline should undergo a 24-hour urine collection and have a 24-hour urine protein quantitation \< 1 g (if both methods are used, a 24-hour urine protein quantitation will be used to determine participant eligibility). Cockcroft/Gault formula:

      Female: CrCl = (140 - Age) × Weight (kg) × 0.85 72 × serum creatinine (mg/dL) Male: CrCl = (140 - years) × weight (kg) × 1.00 72 × serum creatinine (mg/dL)

    8. (INR) ≤ 1.5 × ULN, and prothrombin time (PT) or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
  11. Participants with evidence of status or negative serum pregnancy test (Sexually active, with a non-sterilized male partner) must have a negative serum pregnancy test at the screening visit. WOCBP are women who are not surgically sterile (i.e., have undergone bilateral salpingectomy, bilateral oophorectomy, or total hysterectomy) or are not postmenopausal.
  12. Female participants of childbearing potential or male participants with partners of childbearing potential must take effective measures during the entire course of the trial and 6 months after the treatment

Participants should not be included in the study if they meet any of the following criteria:

  1. Prior treatment with antibody-drug conjugates containing camptothecin or its derivatives (topoisomerase I inhibitors).
  2. Uncontrolled or significant cardiovascular and cerebrovascular diseases, including any of the following:

    1. History of myocardial infarction or symptomatic congestive heart failure ( [NYHA] class II to IV) or uncontrolled myocarditis within 6 months before randomization. Participants with troponin levels above the ULN at screening (as specified by the manufacturer) and without any myocardial infarction-related symptoms should have a cardiology consultation before randomization to rule out myocardial infarction.
    2. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) despite of standard treatment.
    3. History of any arterial thromboembolic events within 6 months prior to randomization, including myocardial infarction, unstable angina, cerebrovascular accident, or .
    4. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolic events within 3 months prior to randomization (thrombosis or catheter-derived thrombosis of caused by implanted venous ports, or superficial vein thrombosis, intermuscular vein thrombosis are not considered serious thromboembolisms).
    5. History of arrhythmia (polymorphic premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, ventricular fibrillation, torsades de pointes) that is symptomatic or requires treatment ( 5.0 Grade 3), atrial fibrillation that is symptomatic or uncontrolled despite treatment, or asymptomatic sustained ventricular tachycardia. Participants whose atrial fibrillation is controlled by medication or whose arrhythmia is controlled by a pacemaker will be allowed to be enrolled in the study.
    6. Fridericia- interval (QTcF) >480 msec. If QTcF is > 480 ms in 1 during the screening period, 3 consecutive ECGs should be performed and the mean QTcF should be calculated. If QTcF is still > 480 ms, the participant will not be enrolled.
    7. History of QT prolongation associated with other drugs that require discontinuation, or any current concomitant medication known to prolong QT interval leading to Torsade de Pointes.
    8. Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death in first-degree relatives under 40 years old.
  3. Non-infectious pneumonitis that requires treatment, or other lung diseases such as a history of interstitial lung disease (ILD)/non-infectious pneumonitis, current ILD/non-infectious pneumonitis, or uncontrolled lung diseases (e.g., pulmonary fibrosis, severe radiation pneumonitis, and acute lung injury) or suspected ILD/non-infectious pneumonitis cannot be ruled out by imaging at screening.
  4. Have a lung-specific intercurrent clinically significant illness including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary embolism within 3 months prior to study randomization, severe asthma, severe [COPD], restrictive lung disorder, significant pleural effusion, post-COVID-19 pulmonary fibrosis, etc.), and any , connective tissue, or inflammatory disorder with pulmonary involvement (or suspected at screening for pulmonary involvement) (e.g., rheumatoid arthritis, Sjogren's syndrome/Sjogren's syndrome, sarcoidosis etc.), and/or prior pneumonectomy.
  5. Prior to the first dose of study drug:

    1. Antibody-based anticancer therapy within 4 weeks, except for receptor activator of nuclear factor-κb ligand (RANKL) inhibitors (eg, denosumab for the treatment of complications resulting from bone metastases).
    2. Hormonal therapy or immunotherapy (based on non-antibody therapy) within 3 weeks.
    3. Fixed-field palliative radiotherapy within 2 weeks, or wide-field palliative radiotherapy within 4 weeks or palliative radiotherapy cumulatively exceeding 30% of bone marrow.
    4. Received oral chemotherapy drugs, small molecule targeted drugs, and Chinese herbal medicines indicated for anti-tumor treatment within 2 weeks or 5 half-lives (whichever is longer).
    5. Had major surgery (craniotomy, thoracotomy, or laparotomy, and other types of surgery considered "major" by the investigator, excluding needle and vascular access) or major traumatic injury within 4 weeks, or expected major surgery during the study, or with severe unhealed wounds, trauma, or ulcers.
    6. Treatment with strong inhibitors or inducers of cytochrome P450 3A4 () within 2 weeks or 5 half-lives (whichever is longer).
    7. (mRNA and non-replicating adenovirus vaccines are not considered live) within 4 weeks.
  6. Participants who had used medications within 14 days prior to the first dose of study drug, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at doses of less than 10 mg/day prednisone (or equivalent to 10 mg/day prednisone) or for prevention of contrast dye allergy.
  7. Known symptomatic central nervous system (CNS) metastasis and/or spinal cord compression and/or carcinomatous meningitis, or a history of carcinoma. Participants with asymptomatic (without neurological symptoms, without the need for corticosteroids or anticonvulsants, and with metastases all ≤ 1.5 cm in diameter) or with brain metastases that are stable after treatment and meet all of the following criteria may be considered for inclusion: (1) measurable lesions outside the CNS; (2) no midbrain, pons, cerebellum, meninges, medulla oblongata, or spinal cord metastases; (3) stable for at least 4 weeks with no new or enlarging metastases ( clearly confirmed by clinical symptoms, signs, and imaging evidence); (4) have discontinued corticosteroids and/or anticonvulsants for at least 2 weeks prior to the first dose of study drug and have recovered from the acute toxicity of radiotherapy. Whole brain radiotherapy or stereotactic radiotherapy must be completed at least 2 weeks prior to study randomization. CNS lesions should be monitored and examined regularly during the study.

    Note: CNS lesions will not be considered target lesions.

  8. Non-remission of adverse events (AEs) after previous anti-cancer treatment, defined as AEs that have not been relieved to ≤ grade 1 or baseline before enrollment according to NCI-CTCAE v5.0 criteria (except for alopecia and pigmentation). Note: Participants with chronic, stable Grade 2 toxicities (defined as not worsening to >Grade 2 for at least 3 months prior to enrollment and manageable with standard of care) that were considered by the investigator to be related to prior anticancer therapy, e.g., fatigue, insomnia, hypomagnesemia, chemotherapy-induced peripheral neuropathy, hypothyroidism stably controlled by replacement therapy, and hypertension stably controlled below 160/100 mmHg by antihypertensives, were eligible for study entry.
  9. Tumor invades surrounding important tissues and organs (such as mediastinal great vessels, superior vena cava and inferior vena cava, pericardium, heart, trachea, esophagus, etc.).
  10. Bleeding within 3 months prior to the first dose of study treatment that is life-threatening and requires blood transfusion or invasive treatment.
  11. Symptomatic abdominopelvic fluid collections, pleural effusions, or pericardial effusions requiring intervention (participants with stable controlled effusions, defined as clinically asymptomatic effusions that do not increase significantly with drain removal or no drainage, for at least 7 days, are allowed).
  12. Participants with varices in the esophagus or stomach that require immediate intervention (e.g., ligation or sclerotherapy), or who are considered by the investigator or a gastroenterologist or hepatologist to be at high risk for bleeding, have evidence of portal hypertension (including splenomegaly on imaging), or have a history of variceal bleeding, must have endoscopic assessment within 3 months prior to the first start of study treatment.
  13. Unhealed gastrointestinal obstruction, perforation, or fistula, or participants at risk of gastrointestinal obstruction or perforation (including but not limited to acute diverticulitis and abdominal abscess), or a history of extensive bowel resection (partial colectomy or extensive small bowel resection accompanied with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea. Note: The digestive tract refers to the muscular tube from the oral cavity to the anal canal, including the oral cavity, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, and ileum), large intestine (cecum, appendix, colon, and rectum), and anal canal.
  14. After endoluminal stenting of the trachea and after stenting of the digestive tract, and the participant did not resume normal diet or defecation.
  15. Participants with biliary obstruction, unless local treatment for obstruction (e.g., endoscopic stent placement or percutaneous liver drainage) has been performed and TBIL has decreased to less than 1.5 × ULN.
  16. Hepatic encephalopathy, hepatorenal syndrome, or cirrhosis with Class B or above.
  17. Significant malnutrition, such as malnutrition requiring parenteral nutrition; except for those who have not used intravenous nutrition within 4 weeks before the first study treatment.
  18. Uncontrolled active infection, including the following:

    1. Infection requiring systemic antibiotic, antiviral, or antifungal therapy.
    2. (HIV) infection, or positive for HIV 1/2 Ab.
    3. Acute or chronic active , defined as hepatitis B surface antigen positive (regardless of the results of antibodies to other antigens) or hepatitis B core antibody positive only (hepatitis B surface antibody negative and hepatitis B e antibody negative), and hepatitis B virus (HBV) DNA ≥ 1 × 10 4 copies/mL or ≥ 2000 IU/mL; or acute or chronic active , defined as hepatitis C virus (HCV) antibody positive and HCV RNA titer above the lower limit of detection.
    4. Active tuberculosis infection, or still receiving anti-tuberculosis treatment, or received anti-tuberculosis treatment within 1 year before the first dose of study drug.
    5. Active syphilis infection or latent syphilis requiring treatment.
  19. History of immunodeficiency diseases, including congenital or acquired immunodeficiency diseases.
  20. History of allogeneic organ transplantation, bone marrow transplantation, or autologous hematopoietic stem cell transplantation (except corneal transplantation).
  21. Pregnant or lactating (may be considered if breastfeeding is discontinued) female participants, or participants planning to become pregnant.
  22. Ineligible for any drug under study. Participants with to trastuzumab, pertuzumab monoclonal antibody, taxanes according to local prescribing information or IBI354 per the IBI354 Investigator's Brochure cannot be enrolled in the study.
  23. Participant has known allergic or reactions to the study treatments, camptothecin and its derivatives, other ADCs/anti-HER2 antibodies, and any .
  24. Complicated with other primary malignant tumors within 3 years or other malignant tumors with active or recurrent risk, excluding radically resected non-melanoma skin cancer (mainly including squamous cell carcinoma of skin and basal cell carcinoma of skin), radically resected carcinoma in situ, and papillary thyroid carcinoma.
  25. Participation in any other interventional clinical study, except for observational (non-interventional) studies or follow-up period after the end of study treatment in interventional studies.
  26. Presence of substance abuse (excessive or inappropriate use of drugs, alcohol, or other harmful substances that may lead to physical, psychological, or social problems) or other acute or chronic diseases or laboratory abnormalities that, in the opinion of the investigator, may interfere with the participant's participation in the clinical study, increase the risk of study participation or drug administration, interfere with the interpretation of study results, or render the participant unsuitable for participation in the study in the judgment of the investigator.
  27. The participant has a neurologic, psychiatric, or psychological illness or social condition that would interfere with trial compliance, substantially increase the risk of adverse events, or prevent the participant from providing written informed consent.
Terms in these criteria, in plain language(46)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    Group A

    IBI354 plus pertuzumab

    Drug: IBI354 · Drug: Pertuzumab

  • Active comparator
    Group C

    THP

    Drug: Trastuzumab · Drug: Docetaxel · Drug: Pertuzumab · Drug: Paclitaxel

  • Experimental
    Group B

    IBI354

    Drug: IBI354

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment

    Defined as time from date of randomisation until the date of objective radiological disease progression according to Blinded Independent Central Review (BICR) using RECIST 1.1 or death by any cause.

    Time frame: Until progression or death, up to 54 months

Secondary outcomes

  1. Progression Free Survival (PFS) by Investigator assessment

    Defined as time from date of randomisation until the date of objective radiological disease progression according to Investigator using RECIST 1.1 or death by any cause.

    Time frame: Until progression or death, up to 54 months

  2. Overall Survival (OS)

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Until death, up to 54 months

  3. Objective Response Rate (ORR) by BICR and Investigator assessment

    ORR is defined as the proportion of participants who have a complete response (CR) or partial response (PR) based on BICR and investigator assessment using RECIST 1.1.

    Time frame: Until progression or death, up to 54 months

  4. Duration of Response (DoR) by BICR and Investigator Assessment

    DoR is defined as the time from date of first detection of objective response until the date of objective radiological disease progression according to BICR and investigator assessment using RECIST 1.1 or death in the absence of progression.

    Time frame: Until progression or death, up to 54 months

  5. Disease control rate (DCR) by BICR and Investigator assessment

    DCR is defined as the proportion of participants in the analysis population achieving disease control (confirmed CR, PR, or stable disease \[SD\]) based on BICR and investigator assessment using RECIST 1.1.

    Time frame: Until progression or death, up to 54 months

  6. Time to response (TTR) by BICR and Investigator assessment

    TTR is defined as the time from randomization to the first CR or PR among participants with confirmed ORR assessed by BICR and investigator per RECIST v1.1.

    Time frame: Until progression or death, up to 54 months

  7. Safety and tolerability of IBI354, alone or with pertuzumab

    Number of AEs according to NCI-CTCAE Version 5.0 per each treatment arm

    Time frame: Until progression or death, up to 54 months

  8. Immunogenicity of IBI354

    Number and percentage of participants who develop anti-drug antibody (ADA) for IBI354

    Time frame: Until progression or death, up to 54 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Apr 2028, 26 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 26 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 30, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Apr 28, 2028
CompletionEst.
May 31, 2030
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07377643
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Feb 10, 2026
Primary completion
Apr 28, 2028 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Feb 25, 2026

Study contacts

Xiaodong Sun
Contact
xiaodong.sun@innoventbio.com
0512-69566088-8095

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2 Antibody-drug Conjugate IBI354

Start the discussion